390 related articles for article (PubMed ID: 18538839)
21. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
Hasselbalch HC
Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
[TBL] [Abstract][Full Text] [Related]
22. [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].
Aumann K; Frey AV; May AM; Hauschke D; Kreutz C; Marx JP; Timmer J; Werner M; Pahl HL
Pathologe; 2013 Nov; 34 Suppl 2():201-9. PubMed ID: 24196613
[TBL] [Abstract][Full Text] [Related]
23. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
Kvasnicka HM; Thiele J
Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
[TBL] [Abstract][Full Text] [Related]
24. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
[TBL] [Abstract][Full Text] [Related]
25. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
26. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
Campr V
Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
[TBL] [Abstract][Full Text] [Related]
27. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
[TBL] [Abstract][Full Text] [Related]
28. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm.
Molitor DCA; Boor P; Buness A; Schneider RK; Teichmann LL; Körber RM; Horvath GL; Koschmieder S; Gütgemann I
Ann Hematol; 2021 Jan; 100(1):97-104. PubMed ID: 33104881
[TBL] [Abstract][Full Text] [Related]
29. Myelofibrosis in Philadelphia chromosome-negative myeloproliferative neoplasms is associated with aberrant karyotypes.
Hauck G; Jonigk D; Göhring G; Kreipe H; Hussein K
Cancer Genet; 2013 Apr; 206(4):116-23. PubMed ID: 23571153
[TBL] [Abstract][Full Text] [Related]
30. Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives.
Barosi G; Rosti V; Gale RP
Leukemia; 2023 Apr; 37(4):725-727. PubMed ID: 36871061
[TBL] [Abstract][Full Text] [Related]
31. Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis.
Tefferi A; Sirhan S; Sun Y; Lasho T; Finke CM; Weisberger J; Bale S; Compton J; LeDuc CA; Pardanani A; Thorland EC; Shevchenko Y; Grodman M; Chung WK
Leuk Res; 2009 May; 33(5):662-4. PubMed ID: 18937974
[TBL] [Abstract][Full Text] [Related]
32. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia.
Koopmans SM; Bot FJ; Lam KH; van Marion AM; de Raeve H; Hebeda KM
Am J Clin Pathol; 2011 Oct; 136(4):618-24. PubMed ID: 21917685
[TBL] [Abstract][Full Text] [Related]
33. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
34. How I Diagnose Primary Myelofibrosis.
Prakash S; Orazi A
Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
[TBL] [Abstract][Full Text] [Related]
35. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
[TBL] [Abstract][Full Text] [Related]
36. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
Thiele J; Kvasnicka HM; Vardiman J
Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
[TBL] [Abstract][Full Text] [Related]
38. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
39. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
Balduini A; Badalucco S; Pugliano MT; Baev D; De Silvestri A; Cattaneo M; Rosti V; Barosi G
PLoS One; 2011; 6(6):e21015. PubMed ID: 21698292
[TBL] [Abstract][Full Text] [Related]
40. Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis.
Andrieux J; Roche-Lestienne C; Geffroy S; Desterke C; Grardel N; Plantier I; Selleslag D; Demory JL; Laï JL; Leleu X; Le Bousse-Kerdiles C; Vandenberghe P
Cancer Genet Cytogenet; 2007 Oct; 178(1):11-6. PubMed ID: 17889703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
